Strides Pharma Peer Comparison

NSE: STAR | BSE: 532531

₹1,019.90

₹36.90 (3.75%)

As on 28-Aug-2026IST

Market cap

₹9,407 Cr

Revenue (TTM)

₹5,004 Cr

P/E Ratio

15.3

P/B Ratio

2.9

Div. Yield

0.5 %

Edit

	Strides Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	9,407	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	5,004	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	635.34	735.15	678.07	666.92	169.62
Net Margin (%)	12.33	26.88	28.10	20.60	6.90
RoE (%)	19.77	19.16	19.73	18.75	20.76
Price to Earnings	15.33	29.25	28.74	28.35	104.74
Price-To-Book	2.87	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	Strides Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	4,858.68	2,519.65	1,937.47	2,893.64	2,275.58
Total Income	5,090.13	2,707.60	2,033.90	2,912.00	2,304.07
Total Expenditure	4,014.13	1,615.47	1,290.54	1,876.44	2,013.55
EBITDA	844.56	904.18	646.93	1,017.20	262.03
Depreciation	202.40	57.73	65.96	315.46	28.58
EBIT	642.16	846.45	580.97	701.74	233.45
Interest	178.55	9.57	0.61	231.29	4.49
Other Income	231.45	187.95	96.43	18.36	28.49
Exceptional Items	-26.84	-49.16	--	--	-5.25
Profit before Tax	668.69	975.67	676.78	488.87	252.20
Provision for Tax	94.17	253.24	135.69	114.20	64.68
Profit after Tax	574.52	722.43	541.09	374.67	187.52

	Strides Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	3,107.57	4,202.90	2,850.49	2,854.36	872.79
Minority Interest	41.77	--	35.90	417.40	--
Non-Current Liabilities	598.54	19.19	13.24	2,100.97	394.49
Current Liabilities	2,895.49	627.48	305.99	1,489.55	1,109.50
Total Liabilities	6,806.56	4,921.88	3,207.85	6,862.28	2,414.58

	Strides Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	3,030.03	1,046.35	1,071.67	5,531.13	509.16
Current Assets	3,612.79	3,803.22	2,133.95	1,331.15	1,859.88
Total Assets	6,806.56	4,921.88	3,207.85	6,862.28	2,414.58
Total Debt*	1,668.69	2.50	0.55	2,421.66	0.00
Net Current Assets	717.30	3,175.74	1,827.96	-158.40	750.38
Contingent Liabilities	118.51	370.49	0.64	64.29	121.23

	Strides Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	702.52	967.57	432.37	1,065.01	-15.14
Cash Flow from Investing Activities	-173.04	-561.67	-334.73	-79.97	18.69
Cash from Financing Activities	-453.41	-798.31	-38.32	-881.32	-91.97
Net Cash Inflow / Outflow	76.07	-392.41	59.32	103.72	-88.42

	Strides Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	18.57	23.39	26.22	13.59	31.24
ROE (%)	20.31	17.16	21.72	13.81	23.02
ROA (%)	9.25	14.91	18.37	5.48	8.90
EBIT Margin (%)	22.15	43.34	38.37	35.79	12.77
Net Margin (%)	11.29	26.68	26.60	12.87	8.14
Cash Profit Margin (%)	10.99	29.72	31.33	23.22	9.47

	Strides Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	6.43	10.45	14.37	44.02	32.59
EBIT Growth (%)	24.89	19.68	20.21	48.22	-1.38
Net Profit Growth (%)	40.33	-5.88	17.27	-5.65	62.02
EPS Growth (%)	-84.52	-5.88	17.25	-10.39	62.02
Book Value Growth (%)	21.78	-0.34	23.77	10.19	13.51

	Strides Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	15.54	29.89	28.38	54.83	103.45
Price / Book Value	2.78	5.14	5.52	6.78	22.39
Dividend Yield (%)	0.53	1.59	0.30	0.52	0.46
EV/EBITDA	9.39	16.93	19.78	20.75	65.23
Market Cap (₹ Cr)	8,643.60	21,592.90	15,219.80	19,292.77	19,398.64

	Strides Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.54	0.00	0.00	0.85	0.00
Short term debt to equity ratio	0.33	0.00	0.00	0.14	--
Current Ratio	1.25	6.06	6.97	0.89	1.68
Quick Ratio	0.68	5.31	5.88	0.67	0.75
Interest Coverage	4.75	102.95	1,110.48	3.11	57.17

	Strides Pharma	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	26.53	7.22	32.65	15.85	9.39
Asset Turnover	1.14	0.54	0.66	0.43	1.08
Receivable days	64.34	26.06	110.70	54.07	31.88
Inventory Days	75.20	65.95	65.86	32.16	126.03
Payable days	218.23	81.01	105.88	140.91	163.79
Cash Conversion Cycle	-78.69	11.00	70.68	-54.68	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.